TickerFacts.

Prokidney Corp. (PROK): Revenue

Annual figures by period end, from SEC filings.

$893.0K
Year ended 2025-12-31
$818.0K
Trailing 12 months to 2026-06-30
2022-12-31: $02023-12-31: $02024-12-31: $76.0K2025-12-31: $893.0K$893.0K
2022-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$893.0Kn/m2026-03-18, From 2025-01-01
2024-12-31$76.0Kn/a2026-03-18, From 2024-01-01
2023-12-31$0n/a2026-03-18, From 2023-01-01
2022-12-31$0n/a2025-03-17, From 2022-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Prokidney Corp. (PROK)2025-12-31$893.0Kn/m
ImageneBio, Inc. (IMA)2025-12-31$800.0K-77.1%
Pluri Inc. (PLUR)2026-06-30$1.02M-24.0%
Inhibrx Biosciences, Inc. (INBX)2025-12-31$1.30M+550.0%
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31$1.31M+99.2%
Cardiff Oncology, Inc. (CRDF)2025-12-31$593.0K-13.2%
Outlook Therapeutics, Inc. (OTLK)2025-09-30$1.41Mn/a
Humacyte, Inc. (HUMA)2025-12-31$2.04Mn/a
Aligos Therapeutics, Inc. (ALGS)2025-12-31$2.19M-39.5%

Compare PROK, IMA, PLUR, INBX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗